Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate
摘要:
We report on the discovery of the new clinical candidate BAY 1003803 as glucocorticoid receptor agonist for the topical treatment of psoriasis or severe atopic dermatitis. In the course of optimizing the amino alcohol series as a highly potent new non-steroidal lead structure, considerations were made as to how physicochemical properties and safety concerns relate to structural motifs. BAY 1003803 demonstrates strong anti-inflammatory activity in vitro paired with a pharmacokinetic profile suitable for topical application.
discovery of two new lead series for the development of glucocorticoid receptor agonists. Firstly, the discovery of tetrahydronaphthalenes led to metabolically stable and dissociated compounds. Their binding mode to the glucocorticoid receptor could be elucidated through an X-ray structure. Closer inspection into the reaction path and analyses of side products revealed a new amino alcohol series also addressing
5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
申请人:Berger Markus
公开号:US20100016338A1
公开(公告)日:2010-01-21
The present invention relates to compounds of formula I,
processes and intermediates for their production and their use as anti-inflammatory agents.
本发明涉及式I的化合物,其生产过程和中间体,以及作为抗炎药物的用途。
[EN] PROCESS FOR THE PREPARATION OF SUBSTITUTED 5-{[2-(ALKOXYMETHYL)-3,3,3-TRIFLUORO-2-HYDROXY-1-PHENYLPROPYL]AMINO}QUINOLIN-2(1H)-ONES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE 5- {[2- (ALCOXYMÉTHYL) -3,3,3-TRIFLUORO-2-HYDROXY-1-PHÉNYLPROPYL] AMINO} QUINOLIN -2 (1H)-ONES SUBSTITUÉES
申请人:BAYER PHARMA AG
公开号:WO2018046684A1
公开(公告)日:2018-03-15
Described is a process as well as intermediates for the preparation of compound of the general formula (I); especially of formula (la) in which the substituents R1, R2, R3, R4 and R5 have the meaning indicated in the present specification.